S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:IMCR

Immunocore News Headlines

$22.95
-1.14 (-4.73%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.85
$23.90
50-Day Range
$22.95
$40.00
52-Week Range
$21.85
$61.99
Volume
259,355 shs
Average Volume
87,892 shs
Market Capitalization
$989.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Immunocore News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Immunocore Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMCR
News Sentiment

0.13

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMCR Articles
This Week

6

0

IMCR Articles
Average Week



Immunocore (NASDAQ:IMCR) News Headlines Today

SourceHeadline
marketbeat.com logoImmunocore (NASDAQ:IMCR) Lifted to "Buy" at Zacks Investment Research
marketbeat.com - January 12 at 3:31 AM
MarketBeat logoImmunocore (NASDAQ:IMCR) Shares Down 8.6%
americanbankingnews.com - January 14 at 3:18 PM
nasdaq.com logoImmunocore Holdings is Now Oversold (IMCR)
nasdaq.com - January 13 at 1:20 PM
MarketBeat logoImmunocore (NASDAQ:IMCR) Reaches New 12-Month Low at $25.30
americanbankingnews.com - January 13 at 10:42 AM
MarketBeat logoImmunocore (NASDAQ:IMCR) Shares Gap Down to $30.39
americanbankingnews.com - January 10 at 12:30 PM
MarketBeat logoComparing Immunocore (NASDAQ:IMCR) and Cullinan Oncology (NASDAQ:CGEM)
americanbankingnews.com - January 10 at 6:18 AM
finance.yahoo.com logoImmunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 10:00 AM
MarketBeat logoImmunocore (NASDAQ:IMCR) Shares Gap Down to $35.44
americanbankingnews.com - December 27 at 12:04 PM
markets.businessinsider.com logoImmunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
markets.businessinsider.com - December 6 at 12:22 PM
finance.yahoo.com logoImmunocore to present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 11 at 8:08 AM
finance.yahoo.com logoImmunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 10 at 9:42 AM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In Immunocore Holdings plc's (NASDAQ:IMCR) Shares?
finance.yahoo.com - November 1 at 11:43 AM
bizjournals.com logoLab Notes: NFlection names new CEO; Immunocore enters into cancer drug partnership
bizjournals.com - October 22 at 2:14 PM
realmoney.thestreet.com logoImmunocore Holdings Plc Sponsored ADR
realmoney.thestreet.com - October 22 at 12:30 AM
finance.yahoo.com logoImmunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
finance.yahoo.com - October 18 at 10:33 AM
finance.yahoo.com logoImmunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
finance.yahoo.com - September 22 at 8:29 PM
finance.yahoo.com logoImmunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
finance.yahoo.com - September 20 at 10:30 AM
finance.yahoo.com logoImmunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
finance.yahoo.com - September 13 at 5:37 PM
finance.yahoo.com logoImmunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
finance.yahoo.com - September 8 at 7:52 AM
markets.businessinsider.com logoImmunocore's Eye Cancer Candidate Under Priority Review In US, Europe
markets.businessinsider.com - August 26 at 8:47 PM
finance.yahoo.com logoImmunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
finance.yahoo.com - August 24 at 8:46 AM
nasdaq.com logoImmunocore Holdings Becomes Oversold (IMCR)
nasdaq.com - August 16 at 3:52 PM
finance.yahoo.com logoImmunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - August 11 at 8:16 AM
wsj.com logoImmunocore Holdings PLC ADR
wsj.com - July 28 at 9:12 AM
finance.yahoo.com logoIs Immunocore Holdings plc (IMCR) A Good Stock To Buy?
finance.yahoo.com - July 27 at 11:00 PM
finance.yahoo.com logoImmunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 4 at 9:18 AM
finance.yahoo.com logoGenesco, Immunocore See Activist Action
finance.yahoo.com - May 28 at 10:43 PM
finanznachrichten.de logoImmunocore Holdings Limited: Immunocore to present at upcoming investor conferences
finanznachrichten.de - May 27 at 9:32 PM
finance.yahoo.com logoImmunocore to present at upcoming investor conferences
finance.yahoo.com - May 27 at 9:32 PM
finance.yahoo.com logoImmunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
finance.yahoo.com - May 18 at 6:02 PM
finanznachrichten.de logoImmunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results
finanznachrichten.de - May 12 at 8:32 AM
finance.yahoo.com logoImmunocore Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 12 at 8:32 AM
finance.yahoo.com logoWhat You Need To Know About Immunocore Holdings plc's (NASDAQ:IMCR) Investor Composition
finance.yahoo.com - May 5 at 2:04 PM
finance.yahoo.com logoImmunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 28 at 7:24 PM
finance.yahoo.com logoImmunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
finance.yahoo.com - April 12 at 5:57 PM
finance.yahoo.com logoImmunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
finance.yahoo.com - March 10 at 9:02 PM
finance.yahoo.com logoImmunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
finance.yahoo.com - February 19 at 8:23 AM
lse.co.uk logoSchroder Uk Pub Regulatory News
lse.co.uk - February 8 at 7:10 PM
Get Immunocore News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.